SCHEMBL2748274

SCHEMBL2748274

COc1cc2c(Oc3ccc4c(C(=O)O)cccc4c3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.64
FLT3 P36888 5/20 0.63
MET P08581 15/20 0.59
KDR P35968 4/20 0.59
INSR P06213 2/20 0.59
AURKA O14965 2/20 0.59
EGFR P00533 2/20 0.59
LCK P06239 2/20 0.59
CSF1R P07333 2/20 0.59
RPS6KB1 P23443 2/20 0.59
FLT4 P35916 2/20 0.59
TEK Q02763 2/20 0.59
MST1R Q04912 2/20 0.59
BTK Q06187 2/20 0.59
PLK4 O00444 1/20 0.59
STK25 O00506 1/20 0.59
CIT O14578 1/20 0.59
CHUK O15111 1/20 0.59
MUSK O15146 1/20 0.59
EPHB6 O15197 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548967 0.93 AXL (0.65) AXLFLT3METKDRINSR
SCHEMBL2747111 0.88 KDR (0.75) AXLFLT3METKDRINSR
SCHEMBL4549007 0.88 FLT3 (0.75) AXLFLT3METKDRINSR
SCHEMBL4549008 0.87 KDR (0.65) AXLFLT3METKDRINSR
SCHEMBL2748792 0.85 KDR (0.60) AXLFLT3METKDRAURKA
SCHEMBL4548851 0.85 FLT3 (0.71) AXLFLT3METKDRINSR
SCHEMBL2748848 0.84 KDR (0.70) METKDRAURKALCKTEK
SCHEMBL2747696 0.82 MET (0.67) AXLFLT3METKDRINSR
SCHEMBL3921794 0.82 AXL (0.65) AXLFLT3METKDRINSR
SCHEMBL2747460 0.81 AXL (0.80) AXLFLT3METKDRINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET AXL 1107/4885FLT3 56/4885MET 3/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET AXL 1107/4885FLT3 56/4885MET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.